<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02440061</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00060865</org_study_id>
    <secondary_id>R01DK097550</secondary_id>
    <nct_id>NCT02440061</nct_id>
  </id_info>
  <brief_title>Ghrelin and Beta Cell Function in Diabetes</brief_title>
  <official_title>Ghrelin Effect on Beta Cell Function in Health and Disease #2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jenny Tong, MD, MPH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ghrelin is a hormone naturally produced in the stomach and the gut. The purpose of this&#xD;
      research study is to determine the role of this gut hormone in the regulation of insulin&#xD;
      secretion from the pancreas and glucose disposal after we eat. The investigators hypothesize&#xD;
      that ghrelin has an effect on the pancreas and on how our body handles glucose after we eat.&#xD;
      The investigators will compare insulin secretion and glucose changes during meal ingestion&#xD;
      while either acyl ghrelin (AG) or saline (salt solution) is being infused through your vein&#xD;
      on separate study days. AG is a form of the ghrelin hormone that has a small modification to&#xD;
      it that allows it to bind to a specific receptor. The investigators hypothesize that AG has&#xD;
      an effect on how the body handles glucose after a meal. AG has been approved by the U.S. Food&#xD;
      and Drug Administration (FDA) for human research only. This study will also involve the use&#xD;
      of a medicine called arginine, which is a naturally occurring product and found in many&#xD;
      nutritional supplements. Its use in this study is investigational. The use of arginine helps&#xD;
      maximize insulin release from the pancreas so the investigators can better examine whether AG&#xD;
      affects insulin secretion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    This protocol was replaced with a different one and therefore discontinued.&#xD;
  </why_stopped>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial insulin secretion (ISR-meal)</measure>
    <time_frame>approximately 8 weeks</time_frame>
    <description>Postprandial insulin secretion (ISR-meal) will be derived from plasma C-peptide concentrations during MTT (0-240 min) using deconvolution with population estimates of C-peptide clearance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Index of β-cell sensitivity to glucose</measure>
    <time_frame>approximately 8 weeks</time_frame>
    <description>Index of β-cell sensitivity to glucose will be calculated as incremental insulin/glucose (I/G) AUC (ΔAUCI/G).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Whole body insulin sensitivity using the Matsuda Index</measure>
    <time_frame>approximately 8 weeks</time_frame>
    <description>The Matsuda Index is a well-known index of insulin sensitivity derived from several glucose and insulin values obtained during a mixed meal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>β-cell function (DI-meal)</measure>
    <time_frame>approximately 8 weeks</time_frame>
    <description>β-cell function (DI-meal) will be calculated as ΔAUCI/G x Matsuda Index</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Study Group: Type 2 Diabetes Mellitus (T2DM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with Type 2 Diabetes Mellitus (T2DM). Subjects will receive AG and saline infusions, but the order of which they receive will be random and they will not be told which one they are receiving on each given visit. Arginine will be used at both study visits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group of healthy subjects. Subjects will receive AG and saline, but the order of which they receive will be random and they will not be told which one they are receiving on each given visit. Arginine will be used at both study visits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Synthetic human AG</intervention_name>
    <description>Synthetic human AG (0.28 μg/kg) bolus over 1 minute followed by 2 μg/kg/hr continuous infusion for 4.5 hours.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Study Group: Type 2 Diabetes Mellitus (T2DM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arginine</intervention_name>
    <description>Arginine hydrochloride (5 g) intravenously over 45 seconds.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Study Group: Type 2 Diabetes Mellitus (T2DM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% saline solution</intervention_name>
    <description>A continuous infusion of 0.9% saline solution (control) for 4.5 hours.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Study Group: Type 2 Diabetes Mellitus (T2DM)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        T2DM study subjects to be considered for the study must meet the following inclusion&#xD;
        criteria:&#xD;
&#xD;
          1. Established T2DM with good to moderate glycemic control&#xD;
&#xD;
          2. HbA1c &lt; 8.5%&#xD;
&#xD;
          3. Diabetes treatment with metformin, sulfonylurea, thiazolidinediones or combination of&#xD;
             these medications; with no use of insulin during the study period&#xD;
&#xD;
          4. BMI ≤ 45.0 kg/m2&#xD;
&#xD;
        Control study subjects will be matched for age- (± 2 years), BMI (± 1.5 kg/m2) and gender&#xD;
        and must meet the following inclusion criteria:&#xD;
&#xD;
          1. HbA1c ≤ 5.7%&#xD;
&#xD;
          2. Fasting plasma glucose ≤ 95 mg/dL&#xD;
&#xD;
          3. BMI ≤ 45.0 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All subjects will be excluded for the following reasons:&#xD;
&#xD;
          1. History of myocardial infarction or arrhythmia within the past year, abnormal&#xD;
             electrocardiogram (ECG) with evidence of ischemia or arrhythmia, history or symptoms&#xD;
             of congestive heart failure&#xD;
&#xD;
          2. Uncontrolled hypertension&#xD;
&#xD;
          3. History or active liver or renal disease (AST or ALT &gt;2x upper limits of normal,&#xD;
             calculated glomerular filtration rate [eGFR] &lt;60 at screening)&#xD;
&#xD;
          4. History of pituitary or adrenal disorders or neuroendocrine tumor&#xD;
&#xD;
          5. Anemia defined as hematocrit &lt;33% at screening&#xD;
&#xD;
          6. Active cancer diagnosis or currently undergoing cancer treatment&#xD;
&#xD;
          7. History of anorexia nervosa or previous gastrointestinal tract surgery&#xD;
&#xD;
          8. Pregnancy or lactation&#xD;
&#xD;
        Control subjects will be excluded for the following reasons:&#xD;
&#xD;
          1. History or clinical evidence of impaired fasting glucose or impaired glucose tolerance&#xD;
             on a 75 g OGTT, established diabetes mellitus, or taking medications prescribed for&#xD;
             diabetes&#xD;
&#xD;
          2. Use of medications that alter insulin sensitivity (i.e. niacin, glucocorticoids,&#xD;
             metformin)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jenny Tong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Center For Living</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>May 7, 2015</study_first_submitted>
  <study_first_submitted_qc>May 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2015</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Jenny Tong, MD, MPH</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Ghrelin</keyword>
  <keyword>age, BMI, and gender matched controls</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

